Clinical Trial Search

Phase 3 N=503 A Study of Flexible-dose Brexpiprazole as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder, the Delphinus Trial

Depressive Disorder · Depression · Depressive Disorder, Major

Primary: Montgomery Asberg Depression Rating Scale (MADRS) — -6.04; -4.86; -4.57 Units on a scale — p=0.0078

Otsuka Pharmaceutical Development &… Results Jun 2018 0.4% serious AE View details

Phase 3 N=76 Aromatase Inhibitors, Alone And In Combination With Growth Hormone In Adolescent Boys With Idiopathic Short Stature

Idiopathic Short Stature

Primary: Change in Height — 14; 17.1; 18.9 Centimeters — p=<0.006

Nemours Children's Clinic Results Jun 2018 10.5% serious AE View details

Phase 3 N=577 Study to Evaluate the Safety and Efficacy of Switching From Regimens Consisting of Boosted Atazanavir or Darunavir Plus Either Emtricitabine/Tenofovir or Abacavir/Lamivudine to Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed HIV-1 Infected Adults

HIV-1 Infection

Primary: Percentage of Participants With HIV-1 RNA ≥ 50 Copies/mL at Week 48 as Determined by the FDA-Defined Snapshot Algorithm — 1.7; 1.7 percentage of participants — p=1.00

Gilead Sciences Results Jun 2018 8.0% serious AE View details

Phase 3 N=102 A Study to Evaluate the Effects of Ocrelizumab on Immune Responses In Participants With Relapsing Forms of Multiple Sclerosis

Multiple Sclerosis, Relapsing-Remitting

Primary: Percentage of Participants With Positive Response to TT Vaccine Measured 8 Weeks After TT Vaccine — 23.9; 54.5 percentage of participants

Hoffmann-La Roche Results Jun 2018 15.7% serious AE View details

Phase 3 N=657 Study to Evaluate the Safety and Efficacy of Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Alafenamide in Human Immunodeficiency Virus (HIV-1) Infected, Antiretroviral Treatment-Naive Adults

HIV-1 Infection

Primary: Percentage of Participants Who Achieved HIV-1 RNA < 50 Copies/mL at Week 48 as Defined by the US FDA-Defined Snapshot Algorithm — 89.4; 92.9 percentage of participants…

Gilead Sciences Results Jun 2018 13.9% serious AE View details

Phase 3 N=1,829 A Multinational Study Comparing the Long-term Efficacy and Safety of Two Medicines, Solifenacin Succinate and Mirabegron Taken Together, or Separately, in Subjects With Symptoms of Overactive Bladder

Urinary Bladder Overactive · Overactive Bladder · Urgency Incontinence

Primary: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) — 126; 134; 596; 61 Participants

Astellas Pharma Europe B.V. Results Jun 2018 3.7% serious AE View details

Phase 3 N=130 Long-Term Safety of Latanoprostene Bunod Ophthalmic Solution 0.024% in Japanese Subjects With OAG or OHT

Glaucoma · Ocular Hypertension

Primary: Change From Baseline in Intraocular Pressure — -4.30; -4.57; -4.76; -4.79 mm Hg — p=<0.001

Bausch & Lomb Incorporated Results Jun 2018 3.9% serious AE View details

Phase 3 N=323 Once-A-Day Pregabalin For Partial Seizures

Partial Seizures · Epilepsies, Partial

Primary: Log Transformed (Loge) 28-day Seizure Rate for All Partial Onset Seizures During the Double-blind Treatment Phase — 2.24; 2.33; 2.32; 1.84 ln (seizures per 28 days)…

Pfizer's Upjohn has merged with Mylan to form… Results Jun 2018 3.7% serious AE View details

Phase 3 N=181 Expanded Controlled Study of Safety and Efficacy of MCI-186 in Patients With Amyotrophic Lateral Sclerosis (ALS)

Amyotrophic Lateral Sclerosis (ALS)

Primary: Change From Baseline in Revised ALS Functional Rating Scale (ALSFRS-R) Score in Full Analysis Set (FAS) Population at 24 Weeks — -5.5; -4.2; -5.4 units on a scale

Tanabe Pharma Corporation Results Jun 2018 42.5% serious AE View details

Phase 3 N=7,903 Comparing the Efficacy of Tiotropium + Olodaterol (5/5 µg) Fixed Dose Combination (FDC) Over Tiotropium 5µg in Reducing Moderate to Severe Exacerbations in Patients With Severe to Very Severe Chronic Obstructive Pulmonary Disease.

Pulmonary Disease, Chronic Obstructive

Primary: Annualised Rate of Moderate to Severe COPD Exacerbations During the Actual Treatment Period. — 0.97; 0.90 Rate per patient-year — p=0.0498

Boehringer Ingelheim Results Jun 2018 21.2% serious AE View details

Phase 3 N=52 Nabilone for Cannabis Dependence: A Pilot Study

Cannabis Dependence · Marijuana Dependence

Primary: Change From Baseline in Cannabis Use at 10 Weeks — 268.8; 286.7; 490.3; 216.9 Ratio

Mclean Hospital Results Jun 2018 0.0% serious AE View details

Phase 3 N=461 Study to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin in Combination With Metformin Compared to Sitagliptin in Combination With Metformin in Adult Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Therapy Alone

Type 2 Diabetes

Primary: Mean Change in HbA1c — -1.41; -1.07 percentage (%) — p=0.0008

AstraZeneca Results Jun 2018 4.8% serious AE View details

Phase 3 N=308 Safety and Efficacy Study of Albiglutide Liquid Drug Product in Type 2 Diabetes Mellitus

Diabetes Mellitus, Type 2

Primary: Change From Baseline in Glycated Hemoglobin (HbA1c) at Week 26 — -1.12; -1.18 Percentage of total hemoglobin — p=0.0002

GlaxoSmithKline Results May 2018 5.2% serious AE View details

Phase 3 N=152 Progesterone (17P, Makena®) for Prolongation of Pregnancy in Women With Preterm Rupture of the Membranes (PROM)

Preterm Delivery

Primary: Gestational Age at Delivery — 29.2; 29.5 weeks.

Obstetrix Medical Group Results May 2018 1.7% serious AE View details

Phase 3 N=343 AM-101 in the Treatment of Acute Tinnitus 2

Tinnitus

Primary: Efficacy: Change in Patient-reported Tinnitus Loudness Questionnaire (TLQ) Improvement From Baseline to Follow up Visit 3 (FUV3) — 0.80; 0.63 units on a scale — p=0.32

Auris Medical, Inc. Results May 2018 1.8% serious AE View details